Dianat-Moghadam H, Heidarifard M, Mahari A, et al. TRAIL in oncology: from recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. Pharmacol Res. 2020. https://doi.org/10.1016/j.phrs.2020.104716.

Article  PubMed  Google Scholar 

Pimentel JM, Zhou JY, Wu GS. The role of TRAIL in apoptosis and immunosurveillance in cancer. Cancers (Basel). 2023;15(10):2752.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amarante-Mendes GP, Griffith TS. Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther. 2015;155:117–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia. 2001;3(6):535–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dubuisson A, Micheau O. Antibodies and derivatives targeting DR4 and DR5 for cancer therapy. Antibodies (Basel). 2017;6(4):16.

Article  PubMed  PubMed Central  Google Scholar 

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

World Health Organization. The Global Cancer Observatory (China). 2021. https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf. Accessed 22 Jan 2024

Kumar S, Baizer L, Callander NS, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022;12(6):98.

Article  PubMed  PubMed Central  Google Scholar 

Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–107.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001;98(3):795–804.

Article  CAS  PubMed  Google Scholar 

Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia. 1999;13(11):1817–24.

Article  CAS  PubMed  Google Scholar 

Jian Y, Chen Y, Geng C, et al. Target and resistance-related proteins of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on myeloma cell lines. Biomed Rep. 2016;4(6):723–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montinaro A, Walczak H. Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries. Cell Death Differ. 2023;30(2):237–49.

Article  CAS  PubMed  Google Scholar 

沙艾特 (aponermin): Chinese prescribing infomation. Wuhan: Wuhan HITECK Biopharmaceutical Co., Ltd; 2023.

National Medical Products Administration. The state Food and Drug Administration approves the launch of aponermin for injection [media release]. https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20231102155258118.html?type=pc&m=. Accessed 2 Nov 2023.

Fang F, Wang AP, Yang SF. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Pharmacol Sin. 2005;26(11):1373–81.

Article  CAS  PubMed  Google Scholar 

Hou J, Qiu L, Zhao Y, et al. A phase1b dose escalation study of recombinant circularly permuted TRAIL in patients with relapsed or refractory multiple myeloma. Am J Clin Oncol. 2018;41(10):1008–14.

Article  CAS  PubMed  Google Scholar 

Xia Z, Leng Y, Fang B, et al. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial. BMC Cancer. 2023;23(1):980.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Y, Giaisi M, Köhler R, et al. Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model. Cancer Lett. 2017;389:70–7.

Article  CAS  PubMed  Google Scholar 

Leng Y, Hu X, Li L, et al. Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells. Hematol Oncol. 2022;40(5):999–1008.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang H, Geng C, Zhou H, et al. Cyclopamine sensitizes multiple myeloma cells to circularly permuted TRAIL-induced apoptosis. Oncol Lett. 2021;21(4):1–7.

Article  ADS  PubMed  Google Scholar 

Liu J, Zhu T, Liu J, et al. Synergistic antitumor effects of circularly permuted TRAIL with doxorubicin in triple-negative breast cancer. Acta Biochim Biophys Sin (Shanghai). 2023;55(8):1247–56.

Article  CAS  PubMed  Google Scholar 

Sun T, Zhu T, Liang X, et al. Effects of recombinant circularly permuted tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) (Recombinant Mutant Human TRAIL) in combination with 5-fluorouracil in human colorectal cancer cell lines HCT116 and SW480. Med Sci Monit. 2018;24:2550–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111(8):3968–77.

Article  CAS  PubMed  Google Scholar 

Rosenberg AS. From mechanism to resistance - changes in the use of dexamethasone in the treatment of multiple myeloma. Leuk Lymphoma. 2023;64(2):283–91.

Article  CAS  PubMed  Google Scholar 

Leng Y, Hou J, Jin J, et al. Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. Cancer Chemother Pharmacol. 2017;79(6):1141–9.

Article  CAS  PubMed  Google Scholar 

Geng C, Hou J, Zhao Y, et al. A multicenter, open-label phase II study of recombinant CPT (circularly permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. Am J Hematol. 2014;89(11):1037–42.

Article  CAS  PubMed  Google Scholar 

Chen WM, Wei P, Yang SF, et al. Transiently elevated AST/LDH are associated with clinical response to recombinant circularly permuted TRAIL (CPT) plus thalidomide in patients with relapsed and/or refractory multiple myeloma [abstract no. 3478]. Blood. 2014;124(21):3478.

Article  Google Scholar 

Leng Y, Qiu L, Hou J, et al. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma. Chin J Cancer. 2016;35(1):86.

Article  PubMed  PubMed Central  Google Scholar 

Wei P, Yang S, Zheng X, et al. Transient elevation of AST or LDH as an early pharmacodynamic biomarker of recombinant circularly permuted TRAIL (CPT) in treating patients with relapsed or refractory multiple myeloma [abstract no. P974]. Haematologica. 2014;99(Suppl. 1):369.

Google Scholar